Cargando…

6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis

BACKGROUND: Adjuvant trastuzumab improves survival outcomes of human epidermal receptor 2 positive early breast cancer patients. Currently, administration of 12 months adjuvant trastuzumab is the standard therapy. However, whether 6 months treatment is non-inferior to the standard 12 months treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bi-Cheng, Xiao, Bo-Ya, Fan, Ji-Quan, Lin, Guo-He, Wang, Chang, Liu, Quentin, Zhao, Yan-Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969267/ https://www.ncbi.nlm.nih.gov/pubmed/33725875 http://dx.doi.org/10.1097/MD.0000000000024995

Ejemplares similares

High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
por: Liu, Yu-Lin, et al.
Publicado: (2015)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
por: Sun, Maoben, et al.
Publicado: (2023)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis
por: Wang, Hong-Bo, et al.
Publicado: (2017)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
por: Akyildiz, Arif, et al.
Publicado: (2023)

Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Deng, Huan, et al.
Publicado: (2020)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Cardiac Protective Effects of Dexrazoxane on Animal Cardiotoxicity Model Induced by Anthracycline Combined With Trastuzumab Is Associated With Upregulation of Calpain-2
por: Zhang, Sheng, et al.
Publicado: (2015)

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
por: Earl, Helena M, et al.
Publicado: (2019)

Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma
por: Yu, Jeong Il, et al.
Publicado: (2016)

Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: A pooled analysis of randomized clinical trials
por: Liu, Xin-Xiu, et al.
Publicado: (2023)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection
por: Jing, Chu-Yu, et al.
Publicado: (2017)

The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma
por: Bao, Junhui, et al.
Publicado: (2020)

Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer
por: Wang, Di, et al.
Publicado: (2016)

Progress in the correlation between PTPN12 gene expression and human tumors
por: Huo, Yu-hu, et al.
Publicado: (2020)

Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?
por: Pilanci, Kezban Nur, et al.
Publicado: (2015)

p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status
por: Wang, Yan, et al.
Publicado: (2021)

Postsurgical treatment with adjuvant transarterial chemoembolization in patients with hepatitis B-related hepatocellular carcinoma: A strobe-compliant article
por: Hu, Hao, et al.
Publicado: (2016)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Glioblastoma multiforme in conus medullaris with intracranial metastasis after postoperative adjuvant therapy
por: Yan, Chengrui, et al.
Publicado: (2017)

NK cells adjuvant therapy shows survival benefits in a gastric mixed signet ring cell carcinoma patient: A case report
por: Jin, Yuan-Yuan, et al.
Publicado: (2021)

HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies
por: Zhang, Qingyu, et al.
Publicado: (2016)

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy
por: Kaehler, Katharina C., et al.
Publicado: (2016)

Long-term functional outcomes of diffuse pigmented villonodular synovitis of knee: The role of adjuvant radiotherapy
por: Chien, Ju Chun, et al.
Publicado: (2021)

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
por: Takahashi, Kenta, et al.
Publicado: (2020)

Nivolumab as adjuvant treatment for a spinal melanocytoma: A case report
por: Hean, Virginie, et al.
Publicado: (2021)

Treatment outcomes of induction chemotherapy combined with intensity-modulated radiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in Southeast China
por: Wang, Peirong, et al.
Publicado: (2021)

Impact of Adjuvant Chemotherapy in Patients With Curatively Resected Stage IV Colorectal Cancer
por: Kobayashi, Hirotoshi, et al.
Publicado: (2015)

Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis
por: Chen, Xuan, et al.
Publicado: (2023)

Long-Term Breast Cancer Patient Outcomes After Adjuvant Radiotherapy Using Intensity-Modulated Radiotherapy or Conventional Tangential Radiotherapy
por: Yang, Jen-Fu, et al.
Publicado: (2016)

Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma
por: Shen, Hong-Yu, et al.
Publicado: (2023)

Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report
por: Jiang, Meng-jie, et al.
Publicado: (2015)

Neoadjuvant intra-arterial versus intravenous chemotherapy in colorectal cancer
por: Peng, Shu hui, et al.
Publicado: (2021)

Distal gastrectomy versus total gastrectomy for distal gastric cancer
por: Liu, Zhen, et al.
Publicado: (2017)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers
por: Lee, Seokwon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lieka021v7mqahlke7rfnpmr62